Inebilizumab for Treatment of IgG4-Related Disease
November 1, 2024
Cool drug in an uncommon disease but one we may encounter at some point in our careers. Inebilizumab is a CD-19 monoclonal antibody (Mab) that is quite effective in controlling the inflammatory process in IgG4-related immune-mediated fibroinflammatory disorders.
